title: Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus.
abstract: To characterize reversible posterior leukoencephalopathy syndrome (RPLS) in systemic lupus erythematosus (SLE) in terms of treatments for resolution and its clinical course, we reviewed 28 cases of RPLS in SLE including our cases in view of the treatment. Of these, 15 cases improved with blood pressure control and 13 required immunosuppressive therapy for activity of SLE presenting neurological manifestations. Patients without immunosuppressants at onset of RPLS more frequently required immunosuppressive therapy to recover it than those precedingly using these agents [31% (4/13) versus 87% (13/15), p = 0.008, chi-square test]. Brain magnetic resonance imaging (MRI) is important for diagnosis of RPLS-SLE in the patient with SLE who develops neurological disturbance and rapidly increasing blood pressure. When 7-day therapy for hypertension and convulsion does not reverse the manifestations, immunosuppressive treatments would be recommended to reverse RPLS.
authors.affiliation: Department of Medicine II, Hokkaido University Graduate School of Medicine, N15W7, Kita-ku, Sapporo 060-8638, Hokkaido, Japan. edaichi@med.hokudai.ac.jp
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Fujieda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kataoka
authors.forename: Toshio
authors.initials: T
authors.lastname: Odani
authors.forename: Kotaro
authors.initials: K
authors.lastname: Otomo
authors.forename: Masaru
authors.initials: M
authors.lastname: Kato
authors.forename: Shinji
authors.initials: S
authors.lastname: Fukaya
authors.forename: Kenji
authors.initials: K
authors.lastname: Oku
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Horita
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Yasuda
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Atsumi
authors.forename: Takao
authors.initials: T
authors.lastname: Koike
mesh_terms: D000328:Adult; D038524:Diffusion Magnetic Resonance Imaging; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D020945:Lupus Vasculitis, Central Nervous System / Q000150:complications* / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D054038:Posterior Leukoencephalopathy Syndrome / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology*
chemical_list: D007166:Immunosuppressive Agents